• Dose: 1 sachet daily, mixed in 150-200 mL water
• Timing: 30-45 minutes before intended sleep
• Onset: Relaxation (L-Theanine) within 30-40 min; full N3 enhancement (Maizinol) at 7-14 days of consistent use
• Duration: No maximum established. No tolerance observed across two RCTs (4-week and multi-week durations)
• Food: May be taken with or without food; absorption not clinically affected

• Pregnancy & lactation: Insufficient safety data for Maizinol in pregnant populations. Individual ingredients generally regarded as safe, but conservative avoidance is recommended.
• Severe renal impairment (eGFR <30): Risk of magnesium accumulation. Dose adjustment or avoidance advised.
• Concurrent MAO inhibitors: Theoretical serotonergic interaction with TPH upregulation. Avoid combination.
• Seizure disorders: GABA-modulating ingredients are generally anticonvulsant, but pharmacodynamic interactions with AEDs warrant caution.
• Major psychiatric disorders on serotonergic medication: While risk is low at food-supplement doses, discuss with treating psychiatrist.
• Known hypersensitivity to any listed ingredient.

• No serious adverse events (SAEs) reported across two RCTs (n=45, 4 weeks; n=80, multi-week)
• Treatment-emergent AEs comparable to placebo (mild GI: 5% vs 3.75%)
• No tolerance development or dose escalation required
• No rebound insomnia upon discontinuation
• No next-day psychomotor impairment or grogginess

Note: Long-term safety data (>8 weeks) is not yet available from controlled trials. Clinical judgment should guide extended use.

• Exogenous melatonin at typical doses (3-10 mg) has not demonstrated significant N3/deep sleep enhancement in meta-analyses.
• Chronic use (>4 weeks) may lead to MT1/MT2 receptor desensitisation, dose escalation, and eventual rebound insomnia in a proportion of users.
• 15-30% of users report next-day grogginess at doses of 3 mg or above, limiting occupational suitability.
• Melatonin is a Schedule H drug in India (prescription-only), creating access and compliance barriers.

"How is this different from a regular sleep supplement?"

Most OTC sleep aids focus on inducing sleep onset (via melatonin, antihistamines, or sedating herbs). REINCARN Night Reboot does not induce sleep - it enhances the restorative architecture of sleep that is already occurring. The target is N3 slow-wave duration, not sleep latency. This makes it suitable for the large population of patients who fall asleep fine but wake unrefreshed.

"What evidence supports the ~+30 min N3 claim?"

Two clinical trials support this claim. Study 1 (Talbott et al. 2023, Journal of Medicinal Food): randomised, double-blind, placebo-controlled, n=45, 4 weeks, actigraphy-validated. The 250mg group increased deep sleep from 64 to 92 minutes - approximately +28 minutes (p=0.05 vs baseline). The paper itself summarises this as "approximately half an hour." Study 2 (KGK Science Inc., SLEEP 2025): triple-blind, placebo-controlled, n=80, actigraphy + EEG, confirmed statistically significant improvements across multiple sleep architecture parameters.

"Can patients use this alongside prescribed sleep medication (Z-drugs, benzodiazepines)?"

Theoretically, yes - with monitoring. The GABAergic components (Mg, Tagara) may have additive effects. In practice, some clinicians use it as a step-down support when tapering patients off sedative-hypnotics. There is no contraindication to concomitant use, but exercise clinical judgment and consider starting during a stable medication period rather than during taper initiation.

"Does it alter REM sleep or dream quality?"

The SLEEP 2025 data specifically confirmed no alteration of REM architecture or REM latency. The enhancement appears selective for N3/SWS. Vitamin B6 at 2 mg has been associated with increased dream vividness in one small study (Ebben 2002), but this has not been reported as an adverse effect in the Maizinol RCT.

"Is there any dependency or withdrawal risk?"

No tolerance or dependency was observed across two RCTs (4-week and multi-week study durations). No rebound insomnia upon discontinuation. The mechanism (enzymatic upregulation) is fundamentally different from receptor agonism (melatonin) or allosteric modulation at sedative sites (benzodiazepines), which makes pharmacological tolerance unlikely.

"How long should a patient trial this before expecting results?"

Patients typically report subjective relaxation from night one (L-Theanine alpha-wave effect, onset 30-40 min). However, the N3 architecture enhancement from Maizinol's TPH/NAT upregulation builds over 7-14 days of consistent use. Advise a minimum 2-week trial before assessing efficacy. Statistically significant deep sleep improvement was measured at Week 2 and Week 4 in the published RCT (Talbott et al. 2023).

"Does it contain any allergens, added sugars, or artificial ingredients?"

The active formulation is free from gluten, soy, dairy, nuts, and added sugars. No artificial colours or preservatives. The Maizinol extract is from corn (Zea mays) leaves - patients with rare corn allergies should be informed, though leaf extract is distinct from corn protein/starch. Glycine contributes negligible calories (~12 kcal from 3 g amino acid).

"Can this be combined with magnesium or B-vitamin supplements the patient is already taking?"

The product contains 200 mg elemental Mg (bisglycinate) and 2 mg B6. For patients already supplementing Mg (e.g., 400 mg for migraines), total intake should be assessed against UL (350 mg supplemental Mg per ICMR/IOM). B6 at 2 mg is well below UL (100 mg). If a patient is already on a comprehensive multi, adjust accordingly - the risk is primarily Mg-related GI effects at very high cumulative doses, not toxicity.

"Is the glycine dose (3 g) a concern for patients with kidney issues?"

3 g glycine is within the range used in clinical studies in healthy populations and is well below doses used therapeutically (up to 60 g/day in schizophrenia research). In patients with normal renal function, no accumulation concern exists. In severe renal impairment (eGFR <30), the magnesium component is the primary concern (accumulation risk). Glycine itself is cleared renally; exercise clinical judgment in CKD stage 4-5.

"Is it suitable for vegetarian/vegan patients?"

Yes. All 7 ingredients are plant-derived or synthetic (non-animal). Glycine is synthesised, not derived from animal collagen. The L-Theanine is from Camellia sinensis. Tart cherry and Tagara are plant extracts. The sachet formulation itself should be verified for excipients (flavouring agents) on final product label.

"How does this fit into a sleep-hygiene-first approach?"

This is positioned as complementary to sleep hygiene, not a replacement. It is most effective when the patient has addressed environmental and behavioural factors (light exposure, temperature, screen time, caffeine timing) but still experiences non-restorative sleep. The formulation works with the body's own mechanisms - so better sleep hygiene amplifies the effect (particularly: dimming lights supports pineal function that Maizinol is enhancing).

"Is it WADA-compliant for competitive athletes?"

None of the 7 ingredients appear on the WADA Prohibited List. Critically, it contains zero melatonin (melatonin itself is not banned by WADA, but its Schedule H status in India creates procurement issues for athletes). The product is suitable for use in competitive sport. However, athletes in tested pools should independently verify batch testing and look for third-party anti-doping certifications (e.g., Informed Sport) on the final product.

"Will it help with post-training recovery and injury rehabilitation?"

The rationale is indirect but physiologically sound: 70-80% of daily GH secretion occurs during N3 deep sleep. GH drives muscle protein synthesis, tendon/collagen repair, and glycogen replenishment. By extending N3 duration (~+28 min), the formulation creates a longer anabolic window during sleep. Additionally, glycine (3 g) is a direct collagen synthesis substrate. The cortisol reduction (-36%) may also improve recovery by reducing catabolic stress.

"Does it cause any morning grogginess that would affect early training sessions?"

No morning impairment was reported across two RCTs (n=45, 4 weeks; n=80, multi-week). This is a key differentiator from melatonin (15-30% grogginess at 3 mg+) and sedative approaches (antihistamines, Z-drugs). The mechanism does not involve sedation - it enhances sleep quality without suppressing arousal capacity. Athletes can take it pre-sleep and train normally at 5-6 AM.

"Can it be used during travel/competition periods with different time zones?"

Yes - importantly, because it does not contain melatonin, it does not phase-shift the circadian clock. It works on sleep quality regardless of when sleep occurs. For jet-lag-related circadian misalignment, exogenous melatonin (timed appropriately) remains the better tool. REINCARN can be used concurrently for quality enhancement once the athlete has established their new sleep window.

"Can I recommend this for my elderly patients?"

The Maizinol RCT enrolled healthy adults (not specifically elderly). However, the individual ingredients (particularly Mg, glycine, valerian) have RCT data in older populations with positive outcomes. N3 naturally declines with age (from ~20% at age 30 to <10% at age 70), making N3 enhancement particularly relevant. Caution: assess renal function (Mg accumulation in eGFR <30) and review polypharmacy for serotonergic interactions. Start with standard dose; no age-specific dose adjustment established.

"What about patients on SSRIs for depression/anxiety who also complain of poor sleep quality?"

SSRIs are known to suppress N3 and REM. This population has a strong rationale for N3 support. At supplement doses, the serotonergic contribution from Maizinol (upstream enzymatic, not direct receptor agonism) is unlikely to cause serotonin syndrome. However, theoretical additive risk exists. Practical approach: use clinical judgment, start during a stable SSRI period, and advise patients to report unusual symptoms (agitation, tremor, myoclonus). The combination is not contraindicated but warrants monitoring.

"Is there any effect on blood pressure or cardiovascular parameters?"

Magnesium bisglycinate (200 mg) may have a mild hypotensive effect (typically 2-5 mmHg systolic in hypertensive populations). Glycine's peripheral vasodilation is transient and nocturnal. No cardiovascular adverse events were reported in the Maizinol RCT. For patients on antihypertensives, consider BP monitoring in the first week. For hypotensive patients, the risk is minimal at these doses but worth noting.

"Can it be used during pregnancy or while breastfeeding?"

Conservative recommendation: avoid during pregnancy. Maizinol UP165 does not have specific gestational safety data. While individual ingredients (Mg, glycine, B6) are commonly used in pregnancy, Tagara (valerian) and Maizinol lack adequate reproductive toxicity studies. For breastfeeding: the risk is likely low (no sedative transfer to infant, no melatonin), but in the absence of specific lactation data, recommend discussing with the patient and using clinical judgment. This is a precautionary stance, not based on known adverse signals.

"My patient has diabetes. Any concerns?"

No direct glycaemic effect expected. Glycine at 3 g has actually shown modest glucose-lowering effects in some studies (improved insulin sensitivity). Magnesium supplementation is associated with improved insulin sensitivity and is often deficient in T2DM patients. No carbohydrate load in the product. Tart cherry anthocyanins have anti-inflammatory properties. Overall, the formulation is neutral-to-positive from a metabolic standpoint. No dose adjustment required.

"What if the patient also takes thyroid medication (levothyroxine)?"

Magnesium can chelate levothyroxine and reduce its absorption. Standard advice: separate levothyroxine from magnesium-containing supplements by at least 4 hours. Since REINCARN is taken pre-sleep and levothyroxine is typically taken first thing in the morning, this separation occurs naturally in most patients. No other ingredient interactions with thyroid medications are known.

"How do I explain this to a patient who 'just wants something to knock them out'?"

This product is not a sedative and will not "knock anyone out." It is designed for patients who can fall asleep but don't wake feeling restored. If a patient's primary complaint is inability to initiate sleep (true insomnia, SOL >45 min), this may not be the best first-line option - CBT-I or short-term pharmacotherapy for insomnia may be more appropriate. REINCARN is best positioned as a long-term quality enhancer, not an acute sleep inducer.

"Is this FSSAI-approved? Do I need to write a prescription?"

REINCARN Night Reboot is classified as a dietary supplement under FSSAI regulations. No prescription is required. It is not a drug under Schedule H or any restricted schedule. Patients can purchase it OTC. However, for complex patients (polypharmacy, comorbidities), your recommendation adds significant value in guiding appropriate use.